Global Biologics Contract Development and Manufacturing M&A Update 2026

M&A activity in the biologics contract development and manufacturing market remained resilient but selective through August 2026, with 15 transactions year-to-date, led primarily by strategic buyers and concentrated in the United States. Buyer interest increasingly favored differentiated, capacity-constrained capabilities with manufacturing and protein-based modalities as the principal areas of focus.

Download this one-pager for the latest biologics CDMO M&A insights:

• M&A activity year-to-date
• Geographic distribution of transactions
• Target manufacturing capabilities
• Target modalities